Get started
Author

Nabeela A. Khan

Observed name: Nabeela Khan
ORCID: 0000-0003-3090-3772
Observed ORCID: 0000-0003-3090-3772
OpenAlex ID: A5073770480
A Role for the Mouse 12/15-Lipoxygenase Pathway in Promoting Epithelial Wound Healing and Host Defense
2005 · Karsten Gronert, Neha Maheshwari, et al. · Journal of Biological Chemistry · 310
PDF
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
2019 · Ying Z. Mazzu, Joshua Armenia, et al. · Clinical Cancer Research · 155
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2019 · Goutam Chakraborty, Joshua Armenia, et al. · Clinical Cancer Research · 112
Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer
2016 · James J. Hsieh, Brandon J. Manley, et al. · Seminars in Cell and Developmental Biology · 53
Host Transcriptomics as a Tool to Identify Diagnostic and Mechanistic Immune Signatures of Tuberculosis
2019 · Julie G. Burel, Mariana Babor, et al. · Frontiers in Immunology · 45
PDF
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
2020 · Ying Z. Mazzu, Joshua Armenia, et al. · Molecular Oncology · 40
PDF
Single-cell profiling reveals distinct subsets of CD14+ monocytes drive blood immune signatures of active tuberculosis
2023 · Hannah Hillman, Nabeela Khan, et al. · Frontiers in Immunology · 33
Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer
2019 · Nabeela A. Khan, Konrad H. Stopsack, et al. · Cancer Epidemiology Biomarkers & Prevention · 28
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy
2017 · Daniel M. Tennenbaum, Brandon J. Manley, et al. · Urologic Oncology Seminars and Original Investigations · 27
Comprehensive Genomic Analysis of Metastatic Non–Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets
2019 · Maria I. Carlo, Nabeela Khan, et al. · JCO Precision Oncology · 19
Abstract 2534: A comparative analysis of fraction genome altered vs tumor mutational count in prostate cancer
2019 · Goutam Chakraborty, Mohammad Atiq, et al. · Cancer Research · 1
Abstract 283: Combination treatment of PARP and SRC inhibitors in BRCA2 mutated prostate cancer
2019 · Nabeela Khan, Goutam Chakraborty, et al. · Cancer Research · 1
BRCA2-RB1 co-loss and ADT resistance in aggressive prostate cancer.
2018 · Goutam Chakraborty, Joshua Armenia, et al. · Journal of Clinical Oncology · 1
The genomic landscape of metastatic non-clear cell renal cell carcinoma.
2017 · Maria Isabel Carlo, Nabeela Khan, et al. · Journal of Clinical Oncology · 1
Figure S2 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
Table S2 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
Table S13 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
Figure S6 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
PDF
Table S7 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
Table S14 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
Table S5 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
Table S12 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
Table S4 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
Supplementary Data from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
Figure S3 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
2023 · Goutam Chakraborty, Joshua Armenia, et al.
Works count: 78
Citation count: 826
H-index: 10
I10-index: 10
Year
Topic
Type